Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

ID: 1515685
recent pressrelease next pressrelease

(Thomson Reuters ONE) -

DUBLIN - July 31, 2017 - Medtronic plc (NYSE:MDT) today announced CE (Conformité
Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve
for the treatment of severe aortic stenosis for symptomatic patients who are at
intermediate, high or extreme risk for open heart surgery. Clinical data for the
Evolut PRO valve was recently unveiled at the American College of Cardiology
(ACC) 66th Annual Scientific Session, and showed high survival, low rates of
stroke, minimal paravalvular leak (PVL) and excellent hemodynamics.

The Evolut PRO device features a unique valve design with an outer wrap that
adds surface area contact between the valve and the native aortic annulus to
further advance valve sealing performance. The biocompatible porcine pericardial
tissue wrap, in addition to other design elements, is incorporated to address
the occurrence of blood leaking through the sides of the valve.

"The Evolut PRO valve has shown impressive clinical outcomes, with low
paravalvular leak and pacemaker rates," said Nicolas M. Van Mieghem, MD,
director of interventional cardiology at Erasmus Medical Center in Rotterdam,
The Netherlands. "With its ease-of-use and deliverability, the Evolut PRO valve
will bring TAVI practice to a higher level, and I look forward to seeing it
utilized in patients across Europe."

The Evolut PRO Clinical Study (N=60) met its primary endpoint at 30 days with
high rates of survival (98.3 percent) and low rates of disabling stroke (1.7
percent). The Evolut PRO valve also showed strong hemodynamic performance with
large aortic valve areas (2.0 ± 0.5 cm(2)) and mean gradients in the single
digits (6.4 ± 2.1 mm Hg) at 30 days. The majority of study subjects (72.4
percent) experienced no/trace PVL and no incidents of moderate or severe PVL
were observed at 30 days. Additionally, improving on the already low rates seen

in Evolut R clinical studies and real-world TVT and FORWARD registries, the rate
of new pacemaker implantation was 10 percent.

Built on the proven platform of the recapturable CoreValve Evolut R System, the
Evolut PRO valve includes a self-expanding nitinol frame with its supra-annular
valve position that helps achieve excellent hemodynamic performance.

"We are excited to introduce the next evolution of our Evolut TAVI platform to
provide physicians in Europe with a comprehensive portfolio to address their
patients'' needs," said Rhonda Robb, vice president and general manager of the
Heart Valve Therapies business, a part of Medtronic''s Cardiac and Vascular

The Evolut PRO System is delivered through the EnVeo(TM) R Delivery Catheter
System and is indicated for vessels down to 5.5 mm. The EnVeo R system features
an InLine Sheath that makes it the lowest delivery platform currently on the
market. It also provides a greater opportunity to treat patients with smaller
vessels through the preferred transfemoral access route.

The 23 mm, 26 mm and 29 mm sizes of the Evolut PRO System received FDA approval
in March 2017 and are available for use in the United States.

In collaboration with leading clinicians, researchers and scientists worldwide,
Medtronic offers the broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services that deliver
clinical and economic value to healthcare consumers and providers around the

About Medtronic
Medtronic plc (, headquartered in Dublin, Ireland, is among
the world''s largest medical technology, services and solutions companies -
alleviating pain, restoring health and extending life for millions of people
around the world. Medtronic employs more than 91,000 people worldwide, serving
physicians, hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to take
healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic''s periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from anticipated


Joey Lomicky
Public Relations

Ryan Weispfenning
Investor Relations

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medtronic plc via GlobeNewswire

More information: http://

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: hugin
print pressrelease  send to a friend  

Date: 07/31/2017 - 08:00
Language: English
News-ID 1515685
Character count: 6670
Firma: Medtronic plc
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Dublin


Number of hits: 487


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 441
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 95

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.


[ more PressReleases ][ RSS-Feed ]